Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
It’s been a very quite year for news from the BoD so far when you compare it to others, and yet a lot is happening. Our resident snoops have been working overtime to dig out snippets of info. Something must be about to erupt to warrant the £5m + investment that is yet to come to fruition.
Best of luck to everyone
From Sept 2018…..
Dr Tim Mitchell, CEO of Sareum, commented: “TYK2 and JAK1 have emerged in recent years as important targets for new drugs with potential to treat a broad range of autoimmune diseases. This has naturally led to some serious interest from the major pharmaceutical companies, including Pfizer, Bristol-Myers Squibb and Celgene having their own clinical and preclinical programmes in this area. With SDC-1801, we believe we are entering this space with a strong candidate that exhibits potentially best-in-class features. We intend to focus our resources on advancing SDC-1801 through preclinical development and into clinical trials over the next 18 months. At the same time, we will continue our discussions with potential licence partners for this exciting drug candidate.”
Sareum has an ongoing co-development agreement with SRI International (Menlo Park, CA, USA) to develop TYK2 inhibitors in autoimmune diseases. Sareum retains commercialisation rights for these and other TYK2 inhibitors with profiles optimised for oncology indications.
Another Great spot potnak, here the journal report mentioned in the RNS…
https://www.jimmunol.org/content/193/7/3278
Took a punt here in 2008, made a few hundred quid. Then started to do some research and read most of T2s post, I would’ve been happy with his 7p prediction that subsequently got exceeded. I’m happy to sit on my 30 K shares and see what happens on this journey all thanks to the one and T2
Here’s hoping you make a speedy recovery if anyone deserves the fruits of SAR, it’s you sir.
Tomorrow
https://www.investis-live.com/gsk/62c7fa19d9438014006f2453/opopp
Fantastic work fellow LTHs I wonder when the bod will make the announcement to the market, surly if what’s been researched and backed by the documents found they can’t keep silent for much longer GLA
Sustained-release, intraoperatively administered
anti-inflammatory drugs, such as DEXYCU (dexamethasone intraocular suspension 9%), are emerging as alternatives to topical drops as a strategy for minimizing inflammation following ocular surgery. In this article, the authors summarize available literature on intraocular dexamethasone and describe the evolution of their administration technique.
https://www.dovepress.com/real-world-experience-with-intracapsular-administration-of-dexamethaso-peer-reviewed-fulltext-article-OPTH
Thanks HBD
Worth watching biotech stocks in US. Lots of money on side line and this sector has been hit badly. Sar/serria will benefit from this imo
https://www.bloomberg.com/news/articles/2022-06-03/bristol-myers-to-pay-4-1-billion-for-lung-cancer-biotech?srnd=deals
Why are we not showcasing here ?
https://beta.asco.org/?s_tnt=161267:0:0&adobe_mc_sdid=SDID%3D587C0C43AEFBB895-463C9C192A69CB82%7CMCORGID%3DFC92401053DA88170A490D4C@AdobeOrg%7CTS%3D1654214400
Above my paywall but plenty of links to tyk2
Resi boffins can connect MMP-9 and MMP12, if appropriate.
https://www.pharmatimes.com/news/birmingham_research_shows_promise_for_spinal_cord_injury_patients_1448677
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872272/
Have also followed this brave ladies battle ever since she was highlighted on this forum a few years ago. I believe she is followed by a few of us on Twitter including Sareum. Thiago out to her family and friends, god bless.
Hi Laza
Thanks for that, I remember Dilly saying late last year that Sra737 was tucked away in his back pocket if needed. He later came out with the news it could be used in conjunction, while he was firmly in a nda during the takeover negotiations, strange that he mentioned sra737. I wonder who or what was behind that move. Maybe over thinking as per usual
Can anyone remember the timeline of the presentations that Dilly was on, was he presenting while his board were in deep negotiations with GSK and others? Am I right in thinking the last mention of SRA737 with atz515 was in Feb